{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:18:12Z","timestamp":1788826692159,"version":"build-2803163510"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1124\/dmd.111.043158","type":"journal-article","created":{"date-parts":[[2012,1,7]],"date-time":"2012-01-07T05:01:38Z","timestamp":1325912498000},"page":"706-716","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions"],"prefix":"10.1016","volume":"40","author":[{"given":"Jialin","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Mohutsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Harrelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Wrighton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.111.043158_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0165-1781(95)02822-6","article-title":"Paroxetine shifts imipramine metabolism","volume":"59","author":"Albers","year":"1996","journal-title":"Psychiatry Res"},{"key":"10.1124\/dmd.111.043158_bib2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00004714-199708000-00008","article-title":"Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers","volume":"17","author":"Alderman","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.111.043158_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1124\/dmd.32.7.715","article-title":"An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates","volume":"32","author":"Andersson","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/chir.530030104","article-title":"Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers","volume":"3","author":"Ayesh","year":"1991","journal-title":"Chirality"},{"key":"10.1124\/dmd.111.043158_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00614553","article-title":"Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide","volume":"34","author":"Back","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib6","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1992.18","article-title":"Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction","volume":"51","author":"Bergstrom","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0090-9556(25)07369-6","article-title":"Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies","volume":"24","author":"Black","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib8","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1211\/jpp.58.5.0008","article-title":"Prediction of hepatic clearance using cryopreserved human hepatocytes: a comparison of serum and serum-free incubations","volume":"58","author":"Blanchard","year":"2006","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib9","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/clpt.1991.49","article-title":"Effect of fluconazole on the disposition of phenytoin","volume":"49","author":"Blum","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF00558224","article-title":"Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine","volume":"37","author":"Br\u00f8sen","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/BF00316471","article-title":"Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine","volume":"44","author":"Br\u00f8sen","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib12","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1365-2125.2005.02483.x","article-title":"Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant","volume":"60","author":"Brown","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib13","first-page":"G584","article-title":"Palmitate uptake by cultured hepatocytes: albumin binding and stagnant layer phenomena","volume":"257","author":"Burczynski","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1124\/dmd.111.043158_bib14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clpt.2005.11.016","article-title":"Comparison of midazolam and simvastatin as cytochrome P450 3A probes","volume":"79","author":"Chung","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s005350300007","article-title":"Influence of albumin binding on the substrate transport mediated by human hepatocyte transporters OATP2 and OATP8","volume":"38","author":"Cui","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1124\/dmd.111.043158_bib16","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1016\/0006-2952(87)90573-9","article-title":"Enzymatic basis of the debrisoquine\/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1\u2032-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency","volume":"36","author":"Dayer","year":"1987","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.drudis.2006.07.012","article-title":"Avoiding physicochemical artefacts in early ADME-Tox experiments","volume":"11","author":"DeWitte","year":"2006","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.111.043158_bib18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00228-004-0762-z","article-title":"Oral administration of a low dose of midazolam (75 \u03bcg) as an in vivo probe for CYP3A activity","volume":"60","author":"Eap","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib19","first-page":"1257","article-title":"Comparison of different approaches to predict metabolic drug-drug interactions","volume":"37","author":"Einolf","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.043158_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.104.075416","article-title":"Mechanism-based inactivation of CYP3A by HIV protease inhibitors","volume":"312","author":"Ernest","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib22","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib23","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0022-3565(25)33338-0","article-title":"Effect of albumin binding on the hepatic transport of rose bengal: surface-mediated dissociation of limited capacity","volume":"223","author":"Forker","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib24","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2125.1989.tb05391.x","article-title":"Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect","volume":"27","author":"Funck-Brentano","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-3565(25)23229-3","article-title":"Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism","volume":"249","author":"Funck-Brentano","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/17425255.4.7.909","article-title":"Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions","volume":"4","author":"Galetin","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.111.043158_bib27","first-page":"2629","article-title":"Blood-tissue exchange in liver and heart: the influence of heterogeneity of capillary transit times","volume":"36","author":"Goresky","year":"1977","journal-title":"Fed Proc"},{"key":"10.1124\/dmd.111.043158_bib28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/00498250701834665","article-title":"Prediction of metabolic clearance using fresh human hepatocytes: comparison with cryopreserved hepatocytes and hepatic microsomes for five benzodiazepines","volume":"38","author":"Hallifax","year":"2008","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.111.043158_bib29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1067\/mcp.2000.106464","article-title":"Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity","volume":"67","author":"Hamelin","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib30","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.0954-6820.1979.tb00729.x","article-title":"The effect of different sulfonamides on phenytoin metabolism in man","volume":"624","author":"Hansen","year":"1979","journal-title":"Acta Med Scand Suppl"},{"key":"10.1124\/dmd.111.043158_bib31","series-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Hardman","year":"2001"},{"key":"10.1124\/dmd.111.043158_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mcp.2000.104788","article-title":"Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"67","author":"Hemeryck","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3109\/03602539709002237","article-title":"Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices","volume":"29","author":"Houston","year":"1997","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.111.043158_bib34","first-page":"13","article-title":"Database analyses for the prediction of in vivo drug-drug interactions from in vitro data","volume":"57","author":"Ito","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.111.043158_bib36","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/(SICI)1099-081X(199605)17:4<273::AID-BDD961>3.0.CO;2-R","article-title":"Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics","volume":"17","author":"Iwatsubo","year":"1996","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.111.043158_bib37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0090-9556(25)07354-4","article-title":"Metoprolol metabolism via cytochrome P4502D6 in ethnic populations","volume":"24","author":"Johnson","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s002280000127","article-title":"Effect of fluconazole on plasma fluvastatin and pravastatin concentrations","volume":"56","author":"Kantola","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib39","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s002280050405","article-title":"Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174","volume":"53","author":"Kaukonen","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib40","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0009-9236(97)90120-X","article-title":"Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers","volume":"62","author":"Kazierad","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib41","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/0091270005280077","article-title":"Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity","volume":"45","author":"Kharasch","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-9236(97)90062-X","article-title":"The effect of sertraline on the pharmacokinetics of desipramine and imipramine","volume":"62","author":"Kurtz","year":"1997","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00228-003-0714-z","article-title":"Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics","volume":"59","author":"Laine","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib44","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1177\/0091270003259216","article-title":"Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone","volume":"43","author":"Lam","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 3","key":"10.1124\/dmd.111.043158_bib45","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/clinids\/12.Supplement_3.S327","article-title":"Drug interactions with fluconazole","volume":"12","author":"Lazar","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1124\/dmd.111.043158_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0009-2797(99)00088-5","article-title":"Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential","volume":"121","author":"Li","year":"1999","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.111.043158_bib47","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1124\/dmd.107.019000","article-title":"Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole","volume":"36","author":"Lu","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib48","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1124\/dmd.107.018796","article-title":"Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole","volume":"36","author":"Lu","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1124\/dmd.106.011346","article-title":"A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data","volume":"35","author":"Lu","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0009-9236(03)00123-1","article-title":"Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe","volume":"74","author":"Majumdar","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib51","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1177\/0091270007300807","article-title":"Effect of aprepitant on the pharmacokinetics of intravenous midazolam","volume":"47","author":"Majumdar","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib52","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0090-9556(24)15021-0","article-title":"The role of CYP2C19 in the metabolism of (+\/\u2212) bufuralol, the prototypic substrate of CYP2D6","volume":"27","author":"Mankowski","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.110.036400","article-title":"Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma","volume":"39","author":"Mao","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/chir.20092","article-title":"Change in enantioselectivity in bufuralol 1\"-hydroxylation by the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6","volume":"17","author":"Masuda","year":"2005","journal-title":"Chirality"},{"key":"10.1124\/dmd.111.043158_bib55","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1177\/00912709922012015","article-title":"Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity","volume":"39","author":"McCrea","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib56","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1124\/dmd.105.005884","article-title":"Prediction of CYP2C9-mediated drug-drug interactions: a comparison using data from recombinant enzymes and human hepatocytes","volume":"33","author":"McGinnity","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib57","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/chir.10212","article-title":"Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s","volume":"15","author":"Narimatsu","year":"2003","journal-title":"Chirality"},{"key":"10.1124\/dmd.111.043158_bib58","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1067\/mcp.2001.114229","article-title":"Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride","volume":"69","author":"Niemi","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib59","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/clpt.1992.78","article-title":"Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects","volume":"51","author":"O'Reilly","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib60","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib61","first-page":"G13","article-title":"Hepatic uptake of albumin-bound substances: albumin receptor concept","volume":"245","author":"Ockner","year":"1983","journal-title":"Am J Physiol"},{"key":"10.1124\/dmd.111.043158_bib62","first-page":"511","article-title":"The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"82","author":"Olkkola","year":"1996","journal-title":"Anesth Analg"},{"key":"10.1124\/dmd.111.043158_bib63","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/clpt.1994.60","article-title":"Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole","volume":"55","author":"Olkkola","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib64","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejpb.2006.06.005","article-title":"Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions","volume":"64","author":"Palmgr\u00e9n","year":"2006","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1124\/dmd.111.043158_bib65","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00004714-199404000-00002","article-title":"Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine","volume":"14","author":"Preskorn","year":"1994","journal-title":"J Clin Psychopharmacol"},{"key":"10.1124\/dmd.111.043158_bib66","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1016\/S0021-9258(17)40992-6","article-title":"Kinetics of bilirubin binding to bovine serum albumin and the effects of palmitate","volume":"252","author":"Reed","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.111.043158_bib67","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ddtec.2004.10.002","article-title":"\u2018In silico\u2019 simulations to assess the \u2018in vivo\u2019 consequences of \u2018in vitro\u2019 metabolic drug-drug interactions","volume":"1","author":"Rostami-Hodjegan","year":"2004","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.111.043158_bib68","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clpt.2005.12.305","article-title":"Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam","volume":"79","author":"Saari","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib69","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1124\/jpet.104.081109","article-title":"Modulation of metoprolol pharmacokinetics and hemodynamics by diphenhydramine coadministration during exercise testing in healthy premenopausal women","volume":"313","author":"Sharma","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/mcp.2003.28","article-title":"Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers","volume":"73","author":"Skinner","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0005-2795(74)90105-6","article-title":"A new method for the measurement of dissociation rates for complexes between small ligands and proteins as applied to the palmitate and bilirubin complexes with serum albumin","volume":"342","author":"Svenson","year":"1974","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.111.043158_bib72","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1124\/dmd.30.6.648","article-title":"Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding","volume":"30","author":"Tang","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2125.1992.tb04111.x","article-title":"Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man","volume":"34","author":"Touchette","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.111.043158_bib74","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib75","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0022-3565(25)20538-9","article-title":"Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man","volume":"259","author":"Turgeon","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib76","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0022-3565(25)22938-X","article-title":"Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias","volume":"255","author":"Turgeon","year":"1990","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.111.043158_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/dmd.111.041210","article-title":"Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition","volume":"40","author":"Vandenbrink","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib78","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/clpt.1990.46","article-title":"Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers","volume":"47","author":"Veronese","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.111.043158_bib79","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.32.2.259","article-title":"Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib80","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1126\/science.6258226","article-title":"Receptor for albumin on the liver cell surface may mediate uptake of fatty acids and other albumin-bound substances","volume":"211","author":"Weisiger","year":"1981","journal-title":"Science"},{"key":"10.1124\/dmd.111.043158_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06653-0","article-title":"Clearance approaches in pharmacology","volume":"39","author":"Wilkinson","year":"1987","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.111.043158_bib82","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1124\/dmd.108.025494","article-title":"Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator","volume":"37","author":"Xu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib83","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.104.002832","article-title":"Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes","volume":"33","author":"Zhao","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.111.043158_bib84","first-page":"550P-1","article-title":"Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo (Abstract)","volume":"39","author":"Zussman","year":"1995","journal-title":"Br J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624059932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624059932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.111.043158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:45:15Z","timestamp":1739904315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624059932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0090955624059932"],"URL":"https:\/\/doi.org\/10.1124\/dmd.111.043158","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictions of Cytochrome P450-Mediated Drug-Drug Interactions Using Cryopreserved Human Hepatocytes: Comparison of Plasma and Protein-Free Media Incubation Conditions","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.111.043158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}